Tarsa Therapeutics completes patient enrollment in Phase III ORACAL trial of oral calcitonin

NewsGuard 100/100 Score
Jul 23 2010

Unigene Laboratories, Inc. (OTCBB: UGNE, http://www.unigene.com) today noted that Tarsa Therapeutics has completed patient enrollment in the Phase III ORACAL trial of Tarsa's oral calcitonin product for the treatment of postmenopausal osteoporosis. Unigene licensed the product to Tarsa and owns 26% of the company.

The ORACAL study is a multinational, randomized, double-blind, placebo-controlled Phase III trial designed to enroll approximately 550 patients. Tarsa also announced that the independent Data Monitoring Committee (DMC) for the ORACAL trial has completed two separate safety reviews of patient data and recommended that the trial proceed as planned.

Source:

Unigene Laboratories, Inc.

Posted in: Drug Trial News | Women's Health News

Tags: , , , , ,

Comments (0)

Suggested Reading

AMG 133 (maridebart cafraglutide) weight loss drug shows promise in early trial
Study reveals inflammation's role in long COVID's lingering effects
Natural killer cells lead the charge in cancer treatment innovation
Study finds patients with long COVID exhibit complement dysregulation with signs of thromboinflammation
Study suggests high levels of vitamin B3 breakdown products are linked to higher risk of mortality, heart attacks, and stroke
CGRP antagonists and dietary changes show promise for migraine treatment
Mapping the Microbiome: Dr. Abidemi Junaid on the Groundbreaking Vagina Chip
Natural compounds show promise in modulating heme breakdown, offering new therapeutic avenues

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
Revvity Signals Software unveils Signals Clinical solution to accelerate critical clinical trial insights and data-driven decisions